FP7 mentoring scheme launched

Enterprise Ireland launched an FP7 mentoring scheme for Irish proposal coordinators in 2012 for which accelopment was selected as a mentor

Lifesaving diagnosis

Saving the lives of mothers and babies, reducing the overall burden of disease, and reducing overall healthcare costs - to say this is an ambitious project would be an understatement. The IMPROvED project (IMproved PRegnancy Outcomes by Early Detection) started in November 2013. This project entails the use of novel metabolite and protein biomarkers to develop a non-invasive, sensitive, specific, and clinically robust blood-screening test.
Pre-eclampsia is the current leading cause of maternal death in Europe and the cause of 70'000-80'000 deaths worldwide annually (and more than 500'000 infant deaths). What the IMPROvED project wants to achieve is to assess and refine two innovative screening tests for the early detection of this complex disorder.
There are three main activities that make this project: Firstly the clinical study, where 5000 first time mothers will be recruited. Secondly the biobank, which will be established to augment accurate clinical metadata. And thirdly the training, in which midwives, clinical academics, PhD students and postdoctoral fellows will be educated by the IMPROvED programme.
Featured on Ireland's national television broadcaster and with a big social media presence, this is a project many people want to see succeed.

Getting to know you

Jeanette was put in contact with Prof Louise Kenny who was planning to submit a stage 1 health proposal (04.09.2011)

Lifesaving diagnosis

Saving the lives of mothers and babies, reducing the overall burden of disease, and reducing overall healthcare costs - to say this is an ambitious project would be an understatement. The IMPROvED project (IMproved PRegnancy Outcomes by Early Detection) started in November 2013. This project entails the use of novel metabolite and protein biomarkers to develop a non-invasive, sensitive, specific, and clinically robust blood-screening test.
Pre-eclampsia is the current leading cause of maternal death in Europe and the cause of 70'000-80'000 deaths worldwide annually (and more than 500'000 infant deaths). What the IMPROvED project wants to achieve is to assess and refine two innovative screening tests for the early detection of this complex disorder.
There are three main activities that make this project: Firstly the clinical study, where 5000 first time mothers will be recruited. Secondly the biobank, which will be established to augment accurate clinical metadata. And thirdly the training, in which midwives, clinical academics, PhD students and postdoctoral fellows will be educated by the IMPROvED programme.
Featured on Ireland's national television broadcaster and with a big social media presence, this is a project many people want to see succeed.

Meeting in a hotel lobby

At short notice, Louise and Jeanette meet the Irish NCP in a hotel lobby in Dublin to discuss the proposal.

Lifesaving diagnosis

Saving the lives of mothers and babies, reducing the overall burden of disease, and reducing overall healthcare costs - to say this is an ambitious project would be an understatement. The IMPROvED project (IMproved PRegnancy Outcomes by Early Detection) started in November 2013. This project entails the use of novel metabolite and protein biomarkers to develop a non-invasive, sensitive, specific, and clinically robust blood-screening test.
Pre-eclampsia is the current leading cause of maternal death in Europe and the cause of 70'000-80'000 deaths worldwide annually (and more than 500'000 infant deaths). What the IMPROvED project wants to achieve is to assess and refine two innovative screening tests for the early detection of this complex disorder.
There are three main activities that make this project: Firstly the clinical study, where 5000 first time mothers will be recruited. Secondly the biobank, which will be established to augment accurate clinical metadata. And thirdly the training, in which midwives, clinical academics, PhD students and postdoctoral fellows will be educated by the IMPROvED programme.
Featured on Ireland's national television broadcaster and with a big social media presence, this is a project many people want to see succeed.

Calls from Africa

Many skype calls with Louise and the co-coordinator Prof Phil Baker late at night during Jeanette`s holiday in Africa

Lifesaving diagnosis

Saving the lives of mothers and babies, reducing the overall burden of disease, and reducing overall healthcare costs - to say this is an ambitious project would be an understatement. The IMPROvED project (IMproved PRegnancy Outcomes by Early Detection) started in November 2013. This project entails the use of novel metabolite and protein biomarkers to develop a non-invasive, sensitive, specific, and clinically robust blood-screening test.
Pre-eclampsia is the current leading cause of maternal death in Europe and the cause of 70'000-80'000 deaths worldwide annually (and more than 500'000 infant deaths). What the IMPROvED project wants to achieve is to assess and refine two innovative screening tests for the early detection of this complex disorder.
There are three main activities that make this project: Firstly the clinical study, where 5000 first time mothers will be recruited. Secondly the biobank, which will be established to augment accurate clinical metadata. And thirdly the training, in which midwives, clinical academics, PhD students and postdoctoral fellows will be educated by the IMPROvED programme.
Featured on Ireland's national television broadcaster and with a big social media presence, this is a project many people want to see succeed.

Revisions, revisions, revisions...

Even more revisions of the proposal document by Jeanette and many versions of the proposal document exchanged

Lifesaving diagnosis

Saving the lives of mothers and babies, reducing the overall burden of disease, and reducing overall healthcare costs - to say this is an ambitious project would be an understatement. The IMPROvED project (IMproved PRegnancy Outcomes by Early Detection) started in November 2013. This project entails the use of novel metabolite and protein biomarkers to develop a non-invasive, sensitive, specific, and clinically robust blood-screening test.
Pre-eclampsia is the current leading cause of maternal death in Europe and the cause of 70'000-80'000 deaths worldwide annually (and more than 500'000 infant deaths). What the IMPROvED project wants to achieve is to assess and refine two innovative screening tests for the early detection of this complex disorder.
There are three main activities that make this project: Firstly the clinical study, where 5000 first time mothers will be recruited. Secondly the biobank, which will be established to augment accurate clinical metadata. And thirdly the training, in which midwives, clinical academics, PhD students and postdoctoral fellows will be educated by the IMPROvED programme.
Featured on Ireland's national television broadcaster and with a big social media presence, this is a project many people want to see succeed.

Fingers crossed

The short proposal is submitted on the 3rd of October 2011.

Lifesaving diagnosis

Saving the lives of mothers and babies, reducing the overall burden of disease, and reducing overall healthcare costs - to say this is an ambitious project would be an understatement. The IMPROvED project (IMproved PRegnancy Outcomes by Early Detection) started in November 2013. This project entails the use of novel metabolite and protein biomarkers to develop a non-invasive, sensitive, specific, and clinically robust blood-screening test.
Pre-eclampsia is the current leading cause of maternal death in Europe and the cause of 70'000-80'000 deaths worldwide annually (and more than 500'000 infant deaths). What the IMPROvED project wants to achieve is to assess and refine two innovative screening tests for the early detection of this complex disorder.
There are three main activities that make this project: Firstly the clinical study, where 5000 first time mothers will be recruited. Secondly the biobank, which will be established to augment accurate clinical metadata. And thirdly the training, in which midwives, clinical academics, PhD students and postdoctoral fellows will be educated by the IMPROvED programme.
Featured on Ireland's national television broadcaster and with a big social media presence, this is a project many people want to see succeed.

Success!

Two weeks before Christmas the results are in and they're positive. A meeting with the 2 SME partners is arranged in London.

Lifesaving diagnosis

Saving the lives of mothers and babies, reducing the overall burden of disease, and reducing overall healthcare costs - to say this is an ambitious project would be an understatement. The IMPROvED project (IMproved PRegnancy Outcomes by Early Detection) started in November 2013. This project entails the use of novel metabolite and protein biomarkers to develop a non-invasive, sensitive, specific, and clinically robust blood-screening test.
Pre-eclampsia is the current leading cause of maternal death in Europe and the cause of 70'000-80'000 deaths worldwide annually (and more than 500'000 infant deaths). What the IMPROvED project wants to achieve is to assess and refine two innovative screening tests for the early detection of this complex disorder.
There are three main activities that make this project: Firstly the clinical study, where 5000 first time mothers will be recruited. Secondly the biobank, which will be established to augment accurate clinical metadata. And thirdly the training, in which midwives, clinical academics, PhD students and postdoctoral fellows will be educated by the IMPROvED programme.
Featured on Ireland's national television broadcaster and with a big social media presence, this is a project many people want to see succeed.

It's been a hard day's night

Louise, Phil, Jeanette and Christoph virtually working day and night

Lifesaving diagnosis

Saving the lives of mothers and babies, reducing the overall burden of disease, and reducing overall healthcare costs - to say this is an ambitious project would be an understatement. The IMPROvED project (IMproved PRegnancy Outcomes by Early Detection) started in November 2013. This project entails the use of novel metabolite and protein biomarkers to develop a non-invasive, sensitive, specific, and clinically robust blood-screening test.
Pre-eclampsia is the current leading cause of maternal death in Europe and the cause of 70'000-80'000 deaths worldwide annually (and more than 500'000 infant deaths). What the IMPROvED project wants to achieve is to assess and refine two innovative screening tests for the early detection of this complex disorder.
There are three main activities that make this project: Firstly the clinical study, where 5000 first time mothers will be recruited. Secondly the biobank, which will be established to augment accurate clinical metadata. And thirdly the training, in which midwives, clinical academics, PhD students and postdoctoral fellows will be educated by the IMPROvED programme.
Featured on Ireland's national television broadcaster and with a big social media presence, this is a project many people want to see succeed.

Time to panic

A corrupt document and limited internet access in Wales for Louise and Phil means the team isn't getting any sleep.

Lifesaving diagnosis

Saving the lives of mothers and babies, reducing the overall burden of disease, and reducing overall healthcare costs - to say this is an ambitious project would be an understatement. The IMPROvED project (IMproved PRegnancy Outcomes by Early Detection) started in November 2013. This project entails the use of novel metabolite and protein biomarkers to develop a non-invasive, sensitive, specific, and clinically robust blood-screening test.
Pre-eclampsia is the current leading cause of maternal death in Europe and the cause of 70'000-80'000 deaths worldwide annually (and more than 500'000 infant deaths). What the IMPROvED project wants to achieve is to assess and refine two innovative screening tests for the early detection of this complex disorder.
There are three main activities that make this project: Firstly the clinical study, where 5000 first time mothers will be recruited. Secondly the biobank, which will be established to augment accurate clinical metadata. And thirdly the training, in which midwives, clinical academics, PhD students and postdoctoral fellows will be educated by the IMPROvED programme.
Featured on Ireland's national television broadcaster and with a big social media presence, this is a project many people want to see succeed.

Crunch time

Submission of the full proposal (08.02.2012)

Lifesaving diagnosis

Saving the lives of mothers and babies, reducing the overall burden of disease, and reducing overall healthcare costs - to say this is an ambitious project would be an understatement. The IMPROvED project (IMproved PRegnancy Outcomes by Early Detection) started in November 2013. This project entails the use of novel metabolite and protein biomarkers to develop a non-invasive, sensitive, specific, and clinically robust blood-screening test.
Pre-eclampsia is the current leading cause of maternal death in Europe and the cause of 70'000-80'000 deaths worldwide annually (and more than 500'000 infant deaths). What the IMPROvED project wants to achieve is to assess and refine two innovative screening tests for the early detection of this complex disorder.
There are three main activities that make this project: Firstly the clinical study, where 5000 first time mothers will be recruited. Secondly the biobank, which will be established to augment accurate clinical metadata. And thirdly the training, in which midwives, clinical academics, PhD students and postdoctoral fellows will be educated by the IMPROvED programme.
Featured on Ireland's national television broadcaster and with a big social media presence, this is a project many people want to see succeed.

It’s getting real

Louise receives invitation for contract negotiations by the EC (19.04.2012)

Lifesaving diagnosis

Saving the lives of mothers and babies, reducing the overall burden of disease, and reducing overall healthcare costs - to say this is an ambitious project would be an understatement. The IMPROvED project (IMproved PRegnancy Outcomes by Early Detection) started in November 2013. This project entails the use of novel metabolite and protein biomarkers to develop a non-invasive, sensitive, specific, and clinically robust blood-screening test.
Pre-eclampsia is the current leading cause of maternal death in Europe and the cause of 70'000-80'000 deaths worldwide annually (and more than 500'000 infant deaths). What the IMPROvED project wants to achieve is to assess and refine two innovative screening tests for the early detection of this complex disorder.
There are three main activities that make this project: Firstly the clinical study, where 5000 first time mothers will be recruited. Secondly the biobank, which will be established to augment accurate clinical metadata. And thirdly the training, in which midwives, clinical academics, PhD students and postdoctoral fellows will be educated by the IMPROvED programme.
Featured on Ireland's national television broadcaster and with a big social media presence, this is a project many people want to see succeed.

Are we all set?

Validation of new FP7 partners guided by, and completion of all contractual documents by Jeanette

Lifesaving diagnosis

Saving the lives of mothers and babies, reducing the overall burden of disease, and reducing overall healthcare costs - to say this is an ambitious project would be an understatement. The IMPROvED project (IMproved PRegnancy Outcomes by Early Detection) started in November 2013. This project entails the use of novel metabolite and protein biomarkers to develop a non-invasive, sensitive, specific, and clinically robust blood-screening test.
Pre-eclampsia is the current leading cause of maternal death in Europe and the cause of 70'000-80'000 deaths worldwide annually (and more than 500'000 infant deaths). What the IMPROvED project wants to achieve is to assess and refine two innovative screening tests for the early detection of this complex disorder.
There are three main activities that make this project: Firstly the clinical study, where 5000 first time mothers will be recruited. Secondly the biobank, which will be established to augment accurate clinical metadata. And thirdly the training, in which midwives, clinical academics, PhD students and postdoctoral fellows will be educated by the IMPROvED programme.
Featured on Ireland's national television broadcaster and with a big social media presence, this is a project many people want to see succeed.

Put your John Hancock here

Loss and replacement of US partner for legal reasons despite trying very hard

Lifesaving diagnosis

Saving the lives of mothers and babies, reducing the overall burden of disease, and reducing overall healthcare costs - to say this is an ambitious project would be an understatement. The IMPROvED project (IMproved PRegnancy Outcomes by Early Detection) started in November 2013. This project entails the use of novel metabolite and protein biomarkers to develop a non-invasive, sensitive, specific, and clinically robust blood-screening test.
Pre-eclampsia is the current leading cause of maternal death in Europe and the cause of 70'000-80'000 deaths worldwide annually (and more than 500'000 infant deaths). What the IMPROvED project wants to achieve is to assess and refine two innovative screening tests for the early detection of this complex disorder.
There are three main activities that make this project: Firstly the clinical study, where 5000 first time mothers will be recruited. Secondly the biobank, which will be established to augment accurate clinical metadata. And thirdly the training, in which midwives, clinical academics, PhD students and postdoctoral fellows will be educated by the IMPROvED programme.
Featured on Ireland's national television broadcaster and with a big social media presence, this is a project many people want to see succeed.

V = Victory

UCC Research Office signs Grant Agreement (07.11.2012)

Lifesaving diagnosis

Saving the lives of mothers and babies, reducing the overall burden of disease, and reducing overall healthcare costs - to say this is an ambitious project would be an understatement. The IMPROvED project (IMproved PRegnancy Outcomes by Early Detection) started in November 2013. This project entails the use of novel metabolite and protein biomarkers to develop a non-invasive, sensitive, specific, and clinically robust blood-screening test.
Pre-eclampsia is the current leading cause of maternal death in Europe and the cause of 70'000-80'000 deaths worldwide annually (and more than 500'000 infant deaths). What the IMPROvED project wants to achieve is to assess and refine two innovative screening tests for the early detection of this complex disorder.
There are three main activities that make this project: Firstly the clinical study, where 5000 first time mothers will be recruited. Secondly the biobank, which will be established to augment accurate clinical metadata. And thirdly the training, in which midwives, clinical academics, PhD students and postdoctoral fellows will be educated by the IMPROvED programme.
Featured on Ireland's national television broadcaster and with a big social media presence, this is a project many people want to see succeed.

Let’s get ready to help

Kick-off meeting in Glengarriff, Cork in November 2012

Lifesaving diagnosis

Saving the lives of mothers and babies, reducing the overall burden of disease, and reducing overall healthcare costs - to say this is an ambitious project would be an understatement. The IMPROvED project (IMproved PRegnancy Outcomes by Early Detection) started in November 2013. This project entails the use of novel metabolite and protein biomarkers to develop a non-invasive, sensitive, specific, and clinically robust blood-screening test.
Pre-eclampsia is the current leading cause of maternal death in Europe and the cause of 70'000-80'000 deaths worldwide annually (and more than 500'000 infant deaths). What the IMPROvED project wants to achieve is to assess and refine two innovative screening tests for the early detection of this complex disorder.
There are three main activities that make this project: Firstly the clinical study, where 5000 first time mothers will be recruited. Secondly the biobank, which will be established to augment accurate clinical metadata. And thirdly the training, in which midwives, clinical academics, PhD students and postdoctoral fellows will be educated by the IMPROvED programme.
Featured on Ireland's national television broadcaster and with a big social media presence, this is a project many people want to see succeed.

Word of mouth

After receiving an email from Andrew, who was recommended to contact accelopment by Andreas, Jeanette responds within 24 hours.

Click chemistry

Medicine could be so much more effective, if only it were personalised. One way of personalising medicine is by using gene therapy. Currently there still are undesirable side effects with gene therapy. These side effects include insertional mutagenesis, toxicity, low efficiency and off-target cutting. Another problem this kind of therapy is facing is how to best deliver the nucleases into cells and tissues.
ClickGene wants to address these side-effects and the questions about delivery. The research objectives are to train 14 ESRs in the field of biomaterials development with specific focus on, siteselective genetic engineering, liposomal nanoparticle drug delivery, and optogenetic diagnostic probes for epigenetic base detection.

Let’s do this

The planned ITN is discussed. And Jeanette thanked technology for giving her the possibility to use the speaker-phone in her car.

Click chemistry

Medicine could be so much more effective, if only it were personalised. One way of personalising medicine is by using gene therapy. Currently there still are undesirable side effects with gene therapy. These side effects include insertional mutagenesis, toxicity, low efficiency and off-target cutting. Another problem this kind of therapy is facing is how to best deliver the nucleases into cells and tissues.
ClickGene wants to address these side-effects and the questions about delivery. The research objectives are to train 14 ESRs in the field of biomaterials development with specific focus on, siteselective genetic engineering, liposomal nanoparticle drug delivery, and optogenetic diagnostic probes for epigenetic base detection.

Friend or foe?

Andreas and Andrew submit under the same H2020 call and agree: There is no conflict of interest.

Click chemistry

Medicine could be so much more effective, if only it were personalised. One way of personalising medicine is by using gene therapy. Currently there still are undesirable side effects with gene therapy. These side effects include insertional mutagenesis, toxicity, low efficiency and off-target cutting. Another problem this kind of therapy is facing is how to best deliver the nucleases into cells and tissues.
ClickGene wants to address these side-effects and the questions about delivery. The research objectives are to train 14 ESRs in the field of biomaterials development with specific focus on, siteselective genetic engineering, liposomal nanoparticle drug delivery, and optogenetic diagnostic probes for epigenetic base detection.

Welcome on board accelopment

All four confirmed partners are happy in hiring accelopment

Click chemistry

Medicine could be so much more effective, if only it were personalised. One way of personalising medicine is by using gene therapy. Currently there still are undesirable side effects with gene therapy. These side effects include insertional mutagenesis, toxicity, low efficiency and off-target cutting. Another problem this kind of therapy is facing is how to best deliver the nucleases into cells and tissues.
ClickGene wants to address these side-effects and the questions about delivery. The research objectives are to train 14 ESRs in the field of biomaterials development with specific focus on, siteselective genetic engineering, liposomal nanoparticle drug delivery, and optogenetic diagnostic probes for epigenetic base detection.

February-Fest?

Proposal preparatory meeting with four partners in Munich on a Saturday morning in February 2014.

Click chemistry

Medicine could be so much more effective, if only it were personalised. One way of personalising medicine is by using gene therapy. Currently there still are undesirable side effects with gene therapy. These side effects include insertional mutagenesis, toxicity, low efficiency and off-target cutting. Another problem this kind of therapy is facing is how to best deliver the nucleases into cells and tissues.
ClickGene wants to address these side-effects and the questions about delivery. The research objectives are to train 14 ESRs in the field of biomaterials development with specific focus on, siteselective genetic engineering, liposomal nanoparticle drug delivery, and optogenetic diagnostic probes for epigenetic base detection.

Can’t think on an empty stomach

WPs, ESR projects, training and dissemination activities fixed within three hours. Bavarian lunch around the corner to wrap up the discussion

Click chemistry

Medicine could be so much more effective, if only it were personalised. One way of personalising medicine is by using gene therapy. Currently there still are undesirable side effects with gene therapy. These side effects include insertional mutagenesis, toxicity, low efficiency and off-target cutting. Another problem this kind of therapy is facing is how to best deliver the nucleases into cells and tissues.
ClickGene wants to address these side-effects and the questions about delivery. The research objectives are to train 14 ESRs in the field of biomaterials development with specific focus on, siteselective genetic engineering, liposomal nanoparticle drug delivery, and optogenetic diagnostic probes for epigenetic base detection.

To me, to you

Andrew and ACCEL team start drafting and exchanging the different sections

Click chemistry

Medicine could be so much more effective, if only it were personalised. One way of personalising medicine is by using gene therapy. Currently there still are undesirable side effects with gene therapy. These side effects include insertional mutagenesis, toxicity, low efficiency and off-target cutting. Another problem this kind of therapy is facing is how to best deliver the nucleases into cells and tissues.
ClickGene wants to address these side-effects and the questions about delivery. The research objectives are to train 14 ESRs in the field of biomaterials development with specific focus on, siteselective genetic engineering, liposomal nanoparticle drug delivery, and optogenetic diagnostic probes for epigenetic base detection.

Finding the missing pieces

March 2014: A few days before the deadline a couple of companies are still needed and 1 drops out

Click chemistry

Medicine could be so much more effective, if only it were personalised. One way of personalising medicine is by using gene therapy. Currently there still are undesirable side effects with gene therapy. These side effects include insertional mutagenesis, toxicity, low efficiency and off-target cutting. Another problem this kind of therapy is facing is how to best deliver the nucleases into cells and tissues.
ClickGene wants to address these side-effects and the questions about delivery. The research objectives are to train 14 ESRs in the field of biomaterials development with specific focus on, siteselective genetic engineering, liposomal nanoparticle drug delivery, and optogenetic diagnostic probes for epigenetic base detection.

Earlier than usual submission

April 2014: Submission 1 day before the deadline with 3 business partners

Click chemistry

Medicine could be so much more effective, if only it were personalised. One way of personalising medicine is by using gene therapy. Currently there still are undesirable side effects with gene therapy. These side effects include insertional mutagenesis, toxicity, low efficiency and off-target cutting. Another problem this kind of therapy is facing is how to best deliver the nucleases into cells and tissues.
ClickGene wants to address these side-effects and the questions about delivery. The research objectives are to train 14 ESRs in the field of biomaterials development with specific focus on, siteselective genetic engineering, liposomal nanoparticle drug delivery, and optogenetic diagnostic probes for epigenetic base detection.

Prepare yourself

In September we receive a great message – the EC has invited us to prepare the grant. In November the “negotiation” process is complete.

Click chemistry

Medicine could be so much more effective, if only it were personalised. One way of personalising medicine is by using gene therapy. Currently there still are undesirable side effects with gene therapy. These side effects include insertional mutagenesis, toxicity, low efficiency and off-target cutting. Another problem this kind of therapy is facing is how to best deliver the nucleases into cells and tissues.
ClickGene wants to address these side-effects and the questions about delivery. The research objectives are to train 14 ESRs in the field of biomaterials development with specific focus on, siteselective genetic engineering, liposomal nanoparticle drug delivery, and optogenetic diagnostic probes for epigenetic base detection.

Let’s click these genes

January 2015: The ClickGene project starts!

Click chemistry

Medicine could be so much more effective, if only it were personalised. One way of personalising medicine is by using gene therapy. Currently there still are undesirable side effects with gene therapy. These side effects include insertional mutagenesis, toxicity, low efficiency and off-target cutting. Another problem this kind of therapy is facing is how to best deliver the nucleases into cells and tissues.
ClickGene wants to address these side-effects and the questions about delivery. The research objectives are to train 14 ESRs in the field of biomaterials development with specific focus on, siteselective genetic engineering, liposomal nanoparticle drug delivery, and optogenetic diagnostic probes for epigenetic base detection.

Time for action

In late 2013 Barbara Häsler asks accelopment for support for a Transdomain COST Action proposal.

One health

The title of this story might sound a bit more confusing to the average Joe than others. What exactly is One Health? Well, let me explain: The One Health concept proposes the need for interdisciplinarity, in particular between natural and social sciences working in human and animal health sectors and with people involved in sustainable environments to alleviate and mitigate the health risks to the global community. The main problem this approach tries to tackle is the fact, that human health and well-being are increasingly affected by multidimensional global challenges.
This project, being a so called COST Action, is a bit different when compared to other projects. COST stands for European Cooperation in Science and Technology and is the longest-running (since 1971) European framework supporting trans-national cooperation among researchers, engineers and scholars across Europe. COST’s goal is to strengthen Europe’s research and innovation capacities.

Ready. Set. Go.

A couple of weeks later an agreement is reached and hard work on proposal starts. Let the work begin.

One health

The title of this story might sound a bit more confusing to the average Joe than others. What exactly is One Health? Well, let me explain: The One Health concept proposes the need for interdisciplinarity, in particular between natural and social sciences working in human and animal health sectors and with people involved in sustainable environments to alleviate and mitigate the health risks to the global community. The main problem this approach tries to tackle is the fact, that human health and well-being are increasingly affected by multidimensional global challenges.
This project, being a so called COST Action, is a bit different when compared to other projects. COST stands for European Cooperation in Science and Technology and is the longest-running (since 1971) European framework supporting trans-national cooperation among researchers, engineers and scholars across Europe. COST’s goal is to strengthen Europe’s research and innovation capacities.

Work never stops

A small team of four (two from RVC, one from LSHTM and Johannes from accelopment) work all day and night on the proposal.

One health

The title of this story might sound a bit more confusing to the average Joe than others. What exactly is One Health? Well, let me explain: The One Health concept proposes the need for interdisciplinarity, in particular between natural and social sciences working in human and animal health sectors and with people involved in sustainable environments to alleviate and mitigate the health risks to the global community. The main problem this approach tries to tackle is the fact, that human health and well-being are increasingly affected by multidimensional global challenges.
This project, being a so called COST Action, is a bit different when compared to other projects. COST stands for European Cooperation in Science and Technology and is the longest-running (since 1971) European framework supporting trans-national cooperation among researchers, engineers and scholars across Europe. COST’s goal is to strengthen Europe’s research and innovation capacities.

Submit!

The proposal is submitted beginning of November and three months later there is good news: The first round of evaluation was passed.

One health

The title of this story might sound a bit more confusing to the average Joe than others. What exactly is One Health? Well, let me explain: The One Health concept proposes the need for interdisciplinarity, in particular between natural and social sciences working in human and animal health sectors and with people involved in sustainable environments to alleviate and mitigate the health risks to the global community. The main problem this approach tries to tackle is the fact, that human health and well-being are increasingly affected by multidimensional global challenges.
This project, being a so called COST Action, is a bit different when compared to other projects. COST stands for European Cooperation in Science and Technology and is the longest-running (since 1971) European framework supporting trans-national cooperation among researchers, engineers and scholars across Europe. COST’s goal is to strengthen Europe’s research and innovation capacities.

Hear me out

Another month later: The Second round of evaluation has been passed and Barbara is invited to a panel hearing.

One health

The title of this story might sound a bit more confusing to the average Joe than others. What exactly is One Health? Well, let me explain: The One Health concept proposes the need for interdisciplinarity, in particular between natural and social sciences working in human and animal health sectors and with people involved in sustainable environments to alleviate and mitigate the health risks to the global community. The main problem this approach tries to tackle is the fact, that human health and well-being are increasingly affected by multidimensional global challenges.
This project, being a so called COST Action, is a bit different when compared to other projects. COST stands for European Cooperation in Science and Technology and is the longest-running (since 1971) European framework supporting trans-national cooperation among researchers, engineers and scholars across Europe. COST’s goal is to strengthen Europe’s research and innovation capacities.

The key is preparation

Johannes supports Barbara in preparation of the presentation for the panel hearing

One health

The title of this story might sound a bit more confusing to the average Joe than others. What exactly is One Health? Well, let me explain: The One Health concept proposes the need for interdisciplinarity, in particular between natural and social sciences working in human and animal health sectors and with people involved in sustainable environments to alleviate and mitigate the health risks to the global community. The main problem this approach tries to tackle is the fact, that human health and well-being are increasingly affected by multidimensional global challenges.
This project, being a so called COST Action, is a bit different when compared to other projects. COST stands for European Cooperation in Science and Technology and is the longest-running (since 1971) European framework supporting trans-national cooperation among researchers, engineers and scholars across Europe. COST’s goal is to strengthen Europe’s research and innovation capacities.

State your case

Two weeks after the evaluation has been passed Barbara presents and defends the project at hearing in Brussels.

One health

The title of this story might sound a bit more confusing to the average Joe than others. What exactly is One Health? Well, let me explain: The One Health concept proposes the need for interdisciplinarity, in particular between natural and social sciences working in human and animal health sectors and with people involved in sustainable environments to alleviate and mitigate the health risks to the global community. The main problem this approach tries to tackle is the fact, that human health and well-being are increasingly affected by multidimensional global challenges.
This project, being a so called COST Action, is a bit different when compared to other projects. COST stands for European Cooperation in Science and Technology and is the longest-running (since 1971) European framework supporting trans-national cooperation among researchers, engineers and scholars across Europe. COST’s goal is to strengthen Europe’s research and innovation capacities.

Success!

On the 11th of April 2014 the project is approved.

One health

The title of this story might sound a bit more confusing to the average Joe than others. What exactly is One Health? Well, let me explain: The One Health concept proposes the need for interdisciplinarity, in particular between natural and social sciences working in human and animal health sectors and with people involved in sustainable environments to alleviate and mitigate the health risks to the global community. The main problem this approach tries to tackle is the fact, that human health and well-being are increasingly affected by multidimensional global challenges.
This project, being a so called COST Action, is a bit different when compared to other projects. COST stands for European Cooperation in Science and Technology and is the longest-running (since 1971) European framework supporting trans-national cooperation among researchers, engineers and scholars across Europe. COST’s goal is to strengthen Europe’s research and innovation capacities.

He found us on here

Dr. Przemyslaw Data finds ACCEL on the web and contacts us in February 2014.

Organic light

It’s one of the main components of something most of us carry in our pockets wherever we go. We look at it all the time – but hardly ever do we give a thought to what technologies make it work. When we come home from work in the evenings many of us will sit in front of one, not thinking about the progress it has made in the last 50 years. From black and white to colour to flat-screens: Displays play an important role in our life. Looking at how advanced our current displays are, it’s hard to think of how they could get even better. But the development in this area is still advancing in ways many of us can’t even imagine. From more vibrant colours to flexible displays, the possibilities are endless.
EXCILIGHT aims to make OLED screens bigger and more affordable. OLED stands for Organic Light Emitting Diode – these are what make up the displays in modern smartphones, such as the Samsung Galaxy S6, the Samsung Galaxy Note 4 or the Motorola Nexus 6. However the problem with OLEDs is that they contain scarce and expensive iridium. The EXCILIGHT project aims to solve this problem by exploring the use of exciplex emitters and thermally activated delayed fluorescence (TADF) in the future production of OLEDs.
A unique point with this project is the number of eastern European beneficiaries, hosting 6 ESRs.

We’re set

Agreement on proposal writing assistance three weeks letter.

Organic light

It’s one of the main components of something most of us carry in our pockets wherever we go. We look at it all the time – but hardly ever do we give a thought to what technologies make it work. When we come home from work in the evenings many of us will sit in front of one, not thinking about the progress it has made in the last 50 years. From black and white to colour to flat-screens: Displays play an important role in our life. Looking at how advanced our current displays are, it’s hard to think of how they could get even better. But the development in this area is still advancing in ways many of us can’t even imagine. From more vibrant colours to flexible displays, the possibilities are endless.
EXCILIGHT aims to make OLED screens bigger and more affordable. OLED stands for Organic Light Emitting Diode – these are what make up the displays in modern smartphones, such as the Samsung Galaxy S6, the Samsung Galaxy Note 4 or the Motorola Nexus 6. However the problem with OLEDs is that they contain scarce and expensive iridium. The EXCILIGHT project aims to solve this problem by exploring the use of exciplex emitters and thermally activated delayed fluorescence (TADF) in the future production of OLEDs.
A unique point with this project is the number of eastern European beneficiaries, hosting 6 ESRs.

Sometimes you have to improvise

Proposal preparation meeting at Stansted Airport in London on 11 March 2014.

Organic light

It’s one of the main components of something most of us carry in our pockets wherever we go. We look at it all the time – but hardly ever do we give a thought to what technologies make it work. When we come home from work in the evenings many of us will sit in front of one, not thinking about the progress it has made in the last 50 years. From black and white to colour to flat-screens: Displays play an important role in our life. Looking at how advanced our current displays are, it’s hard to think of how they could get even better. But the development in this area is still advancing in ways many of us can’t even imagine. From more vibrant colours to flexible displays, the possibilities are endless.
EXCILIGHT aims to make OLED screens bigger and more affordable. OLED stands for Organic Light Emitting Diode – these are what make up the displays in modern smartphones, such as the Samsung Galaxy S6, the Samsung Galaxy Note 4 or the Motorola Nexus 6. However the problem with OLEDs is that they contain scarce and expensive iridium. The EXCILIGHT project aims to solve this problem by exploring the use of exciplex emitters and thermally activated delayed fluorescence (TADF) in the future production of OLEDs.
A unique point with this project is the number of eastern European beneficiaries, hosting 6 ESRs.

Engaging the public

Great experience of partners in training and creative ideas for public engagement and dissemination.

Organic light

It’s one of the main components of something most of us carry in our pockets wherever we go. We look at it all the time – but hardly ever do we give a thought to what technologies make it work. When we come home from work in the evenings many of us will sit in front of one, not thinking about the progress it has made in the last 50 years. From black and white to colour to flat-screens: Displays play an important role in our life. Looking at how advanced our current displays are, it’s hard to think of how they could get even better. But the development in this area is still advancing in ways many of us can’t even imagine. From more vibrant colours to flexible displays, the possibilities are endless.
EXCILIGHT aims to make OLED screens bigger and more affordable. OLED stands for Organic Light Emitting Diode – these are what make up the displays in modern smartphones, such as the Samsung Galaxy S6, the Samsung Galaxy Note 4 or the Motorola Nexus 6. However the problem with OLEDs is that they contain scarce and expensive iridium. The EXCILIGHT project aims to solve this problem by exploring the use of exciplex emitters and thermally activated delayed fluorescence (TADF) in the future production of OLEDs.
A unique point with this project is the number of eastern European beneficiaries, hosting 6 ESRs.

The search continues

Search for additional companies – swings and roundabouts.

Organic light

It’s one of the main components of something most of us carry in our pockets wherever we go. We look at it all the time – but hardly ever do we give a thought to what technologies make it work. When we come home from work in the evenings many of us will sit in front of one, not thinking about the progress it has made in the last 50 years. From black and white to colour to flat-screens: Displays play an important role in our life. Looking at how advanced our current displays are, it’s hard to think of how they could get even better. But the development in this area is still advancing in ways many of us can’t even imagine. From more vibrant colours to flexible displays, the possibilities are endless.
EXCILIGHT aims to make OLED screens bigger and more affordable. OLED stands for Organic Light Emitting Diode – these are what make up the displays in modern smartphones, such as the Samsung Galaxy S6, the Samsung Galaxy Note 4 or the Motorola Nexus 6. However the problem with OLEDs is that they contain scarce and expensive iridium. The EXCILIGHT project aims to solve this problem by exploring the use of exciplex emitters and thermally activated delayed fluorescence (TADF) in the future production of OLEDs.
A unique point with this project is the number of eastern European beneficiaries, hosting 6 ESRs.

Uploading…

Submission on 9 April 2014.

Organic light

It’s one of the main components of something most of us carry in our pockets wherever we go. We look at it all the time – but hardly ever do we give a thought to what technologies make it work. When we come home from work in the evenings many of us will sit in front of one, not thinking about the progress it has made in the last 50 years. From black and white to colour to flat-screens: Displays play an important role in our life. Looking at how advanced our current displays are, it’s hard to think of how they could get even better. But the development in this area is still advancing in ways many of us can’t even imagine. From more vibrant colours to flexible displays, the possibilities are endless.
EXCILIGHT aims to make OLED screens bigger and more affordable. OLED stands for Organic Light Emitting Diode – these are what make up the displays in modern smartphones, such as the Samsung Galaxy S6, the Samsung Galaxy Note 4 or the Motorola Nexus 6. However the problem with OLEDs is that they contain scarce and expensive iridium. The EXCILIGHT project aims to solve this problem by exploring the use of exciplex emitters and thermally activated delayed fluorescence (TADF) in the future production of OLEDs.
A unique point with this project is the number of eastern European beneficiaries, hosting 6 ESRs.

Not quite there yet

Evaluation results on 4 September 2014: 87.8% - high score but not high enough.

Organic light

It’s one of the main components of something most of us carry in our pockets wherever we go. We look at it all the time – but hardly ever do we give a thought to what technologies make it work. When we come home from work in the evenings many of us will sit in front of one, not thinking about the progress it has made in the last 50 years. From black and white to colour to flat-screens: Displays play an important role in our life. Looking at how advanced our current displays are, it’s hard to think of how they could get even better. But the development in this area is still advancing in ways many of us can’t even imagine. From more vibrant colours to flexible displays, the possibilities are endless.
EXCILIGHT aims to make OLED screens bigger and more affordable. OLED stands for Organic Light Emitting Diode – these are what make up the displays in modern smartphones, such as the Samsung Galaxy S6, the Samsung Galaxy Note 4 or the Motorola Nexus 6. However the problem with OLEDs is that they contain scarce and expensive iridium. The EXCILIGHT project aims to solve this problem by exploring the use of exciplex emitters and thermally activated delayed fluorescence (TADF) in the future production of OLEDs.
A unique point with this project is the number of eastern European beneficiaries, hosting 6 ESRs.

Round two

The decision to resubmit is made in November 2014. The plan is to try again in January 2015.

Organic light

It’s one of the main components of something most of us carry in our pockets wherever we go. We look at it all the time – but hardly ever do we give a thought to what technologies make it work. When we come home from work in the evenings many of us will sit in front of one, not thinking about the progress it has made in the last 50 years. From black and white to colour to flat-screens: Displays play an important role in our life. Looking at how advanced our current displays are, it’s hard to think of how they could get even better. But the development in this area is still advancing in ways many of us can’t even imagine. From more vibrant colours to flexible displays, the possibilities are endless.
EXCILIGHT aims to make OLED screens bigger and more affordable. OLED stands for Organic Light Emitting Diode – these are what make up the displays in modern smartphones, such as the Samsung Galaxy S6, the Samsung Galaxy Note 4 or the Motorola Nexus 6. However the problem with OLEDs is that they contain scarce and expensive iridium. The EXCILIGHT project aims to solve this problem by exploring the use of exciplex emitters and thermally activated delayed fluorescence (TADF) in the future production of OLEDs.
A unique point with this project is the number of eastern European beneficiaries, hosting 6 ESRs.

Dotting the i’s, crossing the t’s

The team loses one partner but continues to work hard and updates the proposal to perfection.

Organic light

It’s one of the main components of something most of us carry in our pockets wherever we go. We look at it all the time – but hardly ever do we give a thought to what technologies make it work. When we come home from work in the evenings many of us will sit in front of one, not thinking about the progress it has made in the last 50 years. From black and white to colour to flat-screens: Displays play an important role in our life. Looking at how advanced our current displays are, it’s hard to think of how they could get even better. But the development in this area is still advancing in ways many of us can’t even imagine. From more vibrant colours to flexible displays, the possibilities are endless.
EXCILIGHT aims to make OLED screens bigger and more affordable. OLED stands for Organic Light Emitting Diode – these are what make up the displays in modern smartphones, such as the Samsung Galaxy S6, the Samsung Galaxy Note 4 or the Motorola Nexus 6. However the problem with OLEDs is that they contain scarce and expensive iridium. The EXCILIGHT project aims to solve this problem by exploring the use of exciplex emitters and thermally activated delayed fluorescence (TADF) in the future production of OLEDs.
A unique point with this project is the number of eastern European beneficiaries, hosting 6 ESRs.

Resubmission

Numerous resubmissions follow. 1st resubmission: 7 Jan 2015; 2nd resubmission: 9 Jan 2015; 3rd / final resubmission: 12 Jan 2015.

Organic light

It’s one of the main components of something most of us carry in our pockets wherever we go. We look at it all the time – but hardly ever do we give a thought to what technologies make it work. When we come home from work in the evenings many of us will sit in front of one, not thinking about the progress it has made in the last 50 years. From black and white to colour to flat-screens: Displays play an important role in our life. Looking at how advanced our current displays are, it’s hard to think of how they could get even better. But the development in this area is still advancing in ways many of us can’t even imagine. From more vibrant colours to flexible displays, the possibilities are endless.
EXCILIGHT aims to make OLED screens bigger and more affordable. OLED stands for Organic Light Emitting Diode – these are what make up the displays in modern smartphones, such as the Samsung Galaxy S6, the Samsung Galaxy Note 4 or the Motorola Nexus 6. However the problem with OLEDs is that they contain scarce and expensive iridium. The EXCILIGHT project aims to solve this problem by exploring the use of exciplex emitters and thermally activated delayed fluorescence (TADF) in the future production of OLEDs.
A unique point with this project is the number of eastern European beneficiaries, hosting 6 ESRs.

Success!

5 months later on the 12th June we get the good news: An invitation to grant preparations with the sensational score of 95.4%.

Organic light

It’s one of the main components of something most of us carry in our pockets wherever we go. We look at it all the time – but hardly ever do we give a thought to what technologies make it work. When we come home from work in the evenings many of us will sit in front of one, not thinking about the progress it has made in the last 50 years. From black and white to colour to flat-screens: Displays play an important role in our life. Looking at how advanced our current displays are, it’s hard to think of how they could get even better. But the development in this area is still advancing in ways many of us can’t even imagine. From more vibrant colours to flexible displays, the possibilities are endless.
EXCILIGHT aims to make OLED screens bigger and more affordable. OLED stands for Organic Light Emitting Diode – these are what make up the displays in modern smartphones, such as the Samsung Galaxy S6, the Samsung Galaxy Note 4 or the Motorola Nexus 6. However the problem with OLEDs is that they contain scarce and expensive iridium. The EXCILIGHT project aims to solve this problem by exploring the use of exciplex emitters and thermally activated delayed fluorescence (TADF) in the future production of OLEDs.
A unique point with this project is the number of eastern European beneficiaries, hosting 6 ESRs.

There’s more than banks here

In March ‘09 Emanuela participates in ACCEL`s “Firmensprechtag” (company consulting day) at Biotech Centre in Zürich for a 1.5 hour face-to-face meeting with Jeanette...

Monitoring oxygen

Carrying a mobile phone in our pocket is something most of us do. Why? It’s small enough to fit in the tight space and gives us more freedom in our everyday life (some would claim otherwise – but that’s another discussion). For survivors of incidents like a stroke, a traumatic brain injury, or a cardiac arrest carrying medical equipment, that ensures that there are no repercussions, is more important than having a phone. However these devices should not disrupt daily life in any way, so the dream would be to have a device, which fits in your pocket just like a mobile phone and measures your vitals continuously.
The device we’re talking about is the subject of the OPTO-BRAIN project. The device, called Pocket-NeMo, is about the size of a mobile phone and can measure blood flow non-invasively. Not only that, in certain scenarios the device can also measure intracranial pressure (pressure on the brain). The OPTO in the name is a hint to what technology the device uses. It measures the data using light. By using this technology it is possible to measure the vitals 24/7.
OPTO-BRAIN was submitted to the Eurostars funding scheme, and it’s success means it was in the top 5% of all submitted projects. During the project, the prototype was made ready to enter the market.

Aim for the (Euro)stars

…and Eurostars is identified as the best suitable funding scheme for NeMoDevices now.

Monitoring oxygen

Carrying a mobile phone in our pocket is something most of us do. Why? It’s small enough to fit in the tight space and gives us more freedom in our everyday life (some would claim otherwise – but that’s another discussion). For survivors of incidents like a stroke, a traumatic brain injury, or a cardiac arrest carrying medical equipment, that ensures that there are no repercussions, is more important than having a phone. However these devices should not disrupt daily life in any way, so the dream would be to have a device, which fits in your pocket just like a mobile phone and measures your vitals continuously.
The device we’re talking about is the subject of the OPTO-BRAIN project. The device, called Pocket-NeMo, is about the size of a mobile phone and can measure blood flow non-invasively. Not only that, in certain scenarios the device can also measure intracranial pressure (pressure on the brain). The OPTO in the name is a hint to what technology the device uses. It measures the data using light. By using this technology it is possible to measure the vitals 24/7.
OPTO-BRAIN was submitted to the Eurostars funding scheme, and it’s success means it was in the top 5% of all submitted projects. During the project, the prototype was made ready to enter the market.

Long time no hear

Emanuela contacts Jeanette – they are now ready for an EU proposal (early February 2011)…

Monitoring oxygen

Carrying a mobile phone in our pocket is something most of us do. Why? It’s small enough to fit in the tight space and gives us more freedom in our everyday life (some would claim otherwise – but that’s another discussion). For survivors of incidents like a stroke, a traumatic brain injury, or a cardiac arrest carrying medical equipment, that ensures that there are no repercussions, is more important than having a phone. However these devices should not disrupt daily life in any way, so the dream would be to have a device, which fits in your pocket just like a mobile phone and measures your vitals continuously.
The device we’re talking about is the subject of the OPTO-BRAIN project. The device, called Pocket-NeMo, is about the size of a mobile phone and can measure blood flow non-invasively. Not only that, in certain scenarios the device can also measure intracranial pressure (pressure on the brain). The OPTO in the name is a hint to what technology the device uses. It measures the data using light. By using this technology it is possible to measure the vitals 24/7.
OPTO-BRAIN was submitted to the Eurostars funding scheme, and it’s success means it was in the top 5% of all submitted projects. During the project, the prototype was made ready to enter the market.

More partners, more possibilities

… a non-Swiss partner is missing so Emanuela and Jeanette travel to Germany to visit a company…

Monitoring oxygen

Carrying a mobile phone in our pocket is something most of us do. Why? It’s small enough to fit in the tight space and gives us more freedom in our everyday life (some would claim otherwise – but that’s another discussion). For survivors of incidents like a stroke, a traumatic brain injury, or a cardiac arrest carrying medical equipment, that ensures that there are no repercussions, is more important than having a phone. However these devices should not disrupt daily life in any way, so the dream would be to have a device, which fits in your pocket just like a mobile phone and measures your vitals continuously.
The device we’re talking about is the subject of the OPTO-BRAIN project. The device, called Pocket-NeMo, is about the size of a mobile phone and can measure blood flow non-invasively. Not only that, in certain scenarios the device can also measure intracranial pressure (pressure on the brain). The OPTO in the name is a hint to what technology the device uses. It measures the data using light. By using this technology it is possible to measure the vitals 24/7.
OPTO-BRAIN was submitted to the Eurostars funding scheme, and it’s success means it was in the top 5% of all submitted projects. During the project, the prototype was made ready to enter the market.

This could work

…and put together a consortium consisting of 5 partners from 3 different countries.

Monitoring oxygen

Carrying a mobile phone in our pocket is something most of us do. Why? It’s small enough to fit in the tight space and gives us more freedom in our everyday life (some would claim otherwise – but that’s another discussion). For survivors of incidents like a stroke, a traumatic brain injury, or a cardiac arrest carrying medical equipment, that ensures that there are no repercussions, is more important than having a phone. However these devices should not disrupt daily life in any way, so the dream would be to have a device, which fits in your pocket just like a mobile phone and measures your vitals continuously.
The device we’re talking about is the subject of the OPTO-BRAIN project. The device, called Pocket-NeMo, is about the size of a mobile phone and can measure blood flow non-invasively. Not only that, in certain scenarios the device can also measure intracranial pressure (pressure on the brain). The OPTO in the name is a hint to what technology the device uses. It measures the data using light. By using this technology it is possible to measure the vitals 24/7.
OPTO-BRAIN was submitted to the Eurostars funding scheme, and it’s success means it was in the top 5% of all submitted projects. During the project, the prototype was made ready to enter the market.

It’s submission deadline-day

Emanuela and Jeanette mostly work after hours and manage to submit the proposal in time (late March 2011)

Monitoring oxygen

Carrying a mobile phone in our pocket is something most of us do. Why? It’s small enough to fit in the tight space and gives us more freedom in our everyday life (some would claim otherwise – but that’s another discussion). For survivors of incidents like a stroke, a traumatic brain injury, or a cardiac arrest carrying medical equipment, that ensures that there are no repercussions, is more important than having a phone. However these devices should not disrupt daily life in any way, so the dream would be to have a device, which fits in your pocket just like a mobile phone and measures your vitals continuously.
The device we’re talking about is the subject of the OPTO-BRAIN project. The device, called Pocket-NeMo, is about the size of a mobile phone and can measure blood flow non-invasively. Not only that, in certain scenarios the device can also measure intracranial pressure (pressure on the brain). The OPTO in the name is a hint to what technology the device uses. It measures the data using light. By using this technology it is possible to measure the vitals 24/7.
OPTO-BRAIN was submitted to the Eurostars funding scheme, and it’s success means it was in the top 5% of all submitted projects. During the project, the prototype was made ready to enter the market.

Ups and downs

After a challenging negotiation process with the national funding agencies and the loss of one partner…

Monitoring oxygen

Carrying a mobile phone in our pocket is something most of us do. Why? It’s small enough to fit in the tight space and gives us more freedom in our everyday life (some would claim otherwise – but that’s another discussion). For survivors of incidents like a stroke, a traumatic brain injury, or a cardiac arrest carrying medical equipment, that ensures that there are no repercussions, is more important than having a phone. However these devices should not disrupt daily life in any way, so the dream would be to have a device, which fits in your pocket just like a mobile phone and measures your vitals continuously.
The device we’re talking about is the subject of the OPTO-BRAIN project. The device, called Pocket-NeMo, is about the size of a mobile phone and can measure blood flow non-invasively. Not only that, in certain scenarios the device can also measure intracranial pressure (pressure on the brain). The OPTO in the name is a hint to what technology the device uses. It measures the data using light. By using this technology it is possible to measure the vitals 24/7.
OPTO-BRAIN was submitted to the Eurostars funding scheme, and it’s success means it was in the top 5% of all submitted projects. During the project, the prototype was made ready to enter the market.

Ready, steady, GO!

…the OPTO-BRAIN project is finally launched in January 2012.

Monitoring oxygen

Carrying a mobile phone in our pocket is something most of us do. Why? It’s small enough to fit in the tight space and gives us more freedom in our everyday life (some would claim otherwise – but that’s another discussion). For survivors of incidents like a stroke, a traumatic brain injury, or a cardiac arrest carrying medical equipment, that ensures that there are no repercussions, is more important than having a phone. However these devices should not disrupt daily life in any way, so the dream would be to have a device, which fits in your pocket just like a mobile phone and measures your vitals continuously.
The device we’re talking about is the subject of the OPTO-BRAIN project. The device, called Pocket-NeMo, is about the size of a mobile phone and can measure blood flow non-invasively. Not only that, in certain scenarios the device can also measure intracranial pressure (pressure on the brain). The OPTO in the name is a hint to what technology the device uses. It measures the data using light. By using this technology it is possible to measure the vitals 24/7.
OPTO-BRAIN was submitted to the Eurostars funding scheme, and it’s success means it was in the top 5% of all submitted projects. During the project, the prototype was made ready to enter the market.